advertisement
Abstract #84489 Published in IGR 21-1
New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost
Mehran NA; Sinha S; Razeghinejad REye 2020; 34: 72-88
Reduction of intraocular pressure is the only proven method to treat glaucoma. Initial treatment of glaucoma commonly involves using anti-glaucoma medications either as monotherapy or combination therapy. Studies on aqueous humour dynamics have contributed to our understanding of aqueous outflow mechanisms that have led to the discovery of new drugs. Three new drugs (latanoprostene bunod 0.24%, netarsudil 0.02%, and fixed combination netarsudil 0.02% -latanoprost 0.005%) have been introduced recently in the market with novel mechanisms of action. Latanoprostene bunod 0.024% is a nitric oxide-donating prostaglandin F2α analogue which increases the aqueous outflow both by uveoscleral and trabecular pathways. Netarsudil 0.02% is a potent Rho kinase/norepinephrine transporter inhibitor acting by increasing the trabecular outflow, decreasing the aqueous production, and possibly decreasing the episcleral venous pressure. This review highlights the role of these drugs in the management of glaucoma, with an overview of the major clinical trials on their efficacy, safety, and tolerability.
Glaucoma Service, Wills Eye Hospital, Philadelphia, PA, United States.
Full articleClassification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
11.13.5 Other (Part of: 11 Medical treatment > 11.13 Combination therapy)
11.14 Investigational drugs; pharmacological experiments (Part of: 11 Medical treatment)